|
ATE491022T1
(de)
|
2005-10-18 |
2010-12-15 |
Nat Jewish Health |
Konditionell immortalisierte adulte langzeit- stammzellen und verfahren zur herstellung und verwendung von solchen zellen
|
|
EP2285832B1
(en)
|
2008-05-16 |
2020-08-26 |
Taiga Biotechnologies, Inc. |
Antibodies and processes for preparing the same
|
|
ES2681478T3
(es)
|
2008-08-28 |
2018-09-13 |
Taiga Biotechnologies, Inc. |
Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
|
|
ES2856179T3
(es)
|
2012-07-20 |
2021-09-27 |
Taiga Biotechnologies Inc |
Reconstitución y autorreconstitución potenciadas del compartimento hematopoyético
|
|
AU2013379772B2
(en)
*
|
2013-03-01 |
2018-09-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing enriched populations of tumor-reactive T cells from tumor
|
|
US10272115B2
(en)
|
2013-03-11 |
2019-04-30 |
Taiga Biotechnologies, Inc. |
Production and use of red blood cells
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
EP3082853A2
(en)
|
2013-12-20 |
2016-10-26 |
The Broad Institute, Inc. |
Combination therapy with neoantigen vaccine
|
|
ES2980788T3
(es)
|
2014-04-10 |
2024-10-03 |
H Lee Moffitt Cancer Ct & Res |
Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva
|
|
CA2963362A1
(en)
*
|
2014-10-02 |
2016-04-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
|
|
JP6599450B2
(ja)
*
|
2014-10-02 |
2019-10-30 |
アメリカ合衆国 |
がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
|
|
US10993997B2
(en)
|
2014-12-19 |
2021-05-04 |
The Broad Institute, Inc. |
Methods for profiling the t cell repertoire
|
|
EP3234193B1
(en)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
US10544392B2
(en)
|
2015-05-01 |
2020-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
WO2016187508A2
(en)
|
2015-05-20 |
2016-11-24 |
The Broad Institute Inc. |
Shared neoantigens
|
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
EP3368689B1
(en)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Composition for modulating immune responses by use of immune cell gene signature
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
US11001622B2
(en)
|
2015-11-19 |
2021-05-11 |
The Brigham And Women's Hospital, Inc. |
Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
|
|
EP3402512A4
(en)
*
|
2016-01-11 |
2019-09-25 |
Armo Biosciences, Inc. |
INTERLEUKIN-10 IN THE PREPARATION OF ANTIGEN-SPECIFIC CD8 + T CELLS AND METHOD FOR THE USE THEREOF
|
|
CA3030156A1
(en)
|
2016-07-07 |
2018-01-11 |
Iovance Biotherapeutics, Inc. |
Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
US20210292696A1
(en)
|
2016-09-22 |
2021-09-23 |
Corning Incorporated |
Gravity flow cell culture devices, systems, and methods of use thereof
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
MX2019004707A
(es)
|
2016-10-26 |
2019-08-12 |
Iovance Biotherapeutics Inc |
Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
US12227578B2
(en)
|
2016-11-11 |
2025-02-18 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
|
|
KR102618948B1
(ko)
|
2016-11-17 |
2023-12-27 |
이오반스 바이오테라퓨틱스, 인크. |
잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
|
|
WO2018102678A1
(en)
|
2016-12-02 |
2018-06-07 |
Taiga Biotechnologies, Inc. |
Nanoparticle formulations
|
|
WO2018129336A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
US20200121719A1
(en)
|
2017-01-06 |
2020-04-23 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
US11254913B1
(en)
|
2017-03-29 |
2022-02-22 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
CA3062874A1
(en)
|
2017-05-10 |
2018-11-16 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2018209324A2
(en)
|
2017-05-11 |
2018-11-15 |
The Broad Institute, Inc. |
Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
MX2019014023A
(es)
|
2017-05-24 |
2020-02-17 |
Novartis Ag |
Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
|
|
US11819517B2
(en)
|
2017-06-05 |
2023-11-21 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
US11897953B2
(en)
|
2017-06-14 |
2024-02-13 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
US10149898B2
(en)
|
2017-08-03 |
2018-12-11 |
Taiga Biotechnologies, Inc. |
Methods and compositions for the treatment of melanoma
|
|
JP6731114B2
(ja)
|
2017-08-03 |
2020-07-29 |
タイガ バイオテクノロジーズ，インク． |
メラノーマの処置のための方法および組成物
|
|
EP3695408A4
(en)
|
2017-10-02 |
2021-12-15 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
US11732257B2
(en)
|
2017-10-23 |
2023-08-22 |
Massachusetts Institute Of Technology |
Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
|
|
US12018080B2
(en)
|
2017-11-13 |
2024-06-25 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
JP7557367B2
(ja)
|
2017-11-17 |
2024-09-27 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
細針吸引及び小生検からのｔｉｌ拡大培養
|
|
CA3083118A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
JP7565795B2
(ja)
|
2017-12-15 |
2024-10-11 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
BR112020013848A2
(pt)
|
2018-01-08 |
2020-12-01 |
Iovance Biotherapeutics, Inc. |
métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
SG11202009170UA
(en)
|
2018-03-29 |
2020-10-29 |
Iovance Biotherapeutics Inc |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
CN112368003A
(zh)
|
2018-04-27 |
2021-02-12 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞的基因编辑及其在免疫治疗中的用途
|
|
WO2019217753A1
(en)
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
|
|
MX2021002887A
(es)
|
2018-09-20 |
2021-06-04 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores (tils) a partir de muestras de tumor crioconservadas.
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
|
JOP20210094A1
(ar)
|
2018-11-05 |
2023-01-30 |
Iovance Biotherapeutics Inc |
عمليات لإنتاج الخلايا الليمفاوية للورم الارتشاحي واستخداماتها في العلاج المناعي
|
|
BR112021008549A2
(pt)
|
2018-11-05 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
|
|
WO2020096927A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
EP3877512A2
(en)
|
2018-11-05 |
2021-09-15 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
EP3898949A1
(en)
|
2018-12-19 |
2021-10-27 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
WO2020191079A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
AU2020272664A1
(en)
|
2019-04-08 |
2021-11-04 |
Taiga Biotechnologies, Inc. |
Compositions and methods for the cry opreservation of immune cells
|
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US12370217B2
(en)
|
2019-05-14 |
2025-07-29 |
Htyr Acquisition Llc |
Compositions and methods for treating T cell exhaustion
|
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
JP7640047B2
(ja)
*
|
2019-07-10 |
2025-03-05 |
国立研究開発法人国立がん研究センター |
がん細胞を特異的に攻撃しているｔ細胞を同定するための特異的マーカー
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
CN110484504B
(zh)
*
|
2019-08-28 |
2022-10-14 |
复旦大学附属中山医院 |
一种用于免疫治疗原发性肝细胞肝癌的细胞亚群及其制备方法
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
JP7340144B2
(ja)
*
|
2019-10-02 |
2023-09-07 |
アメリカ合衆国 |
がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
|
|
JP6878544B2
(ja)
*
|
2019-10-02 |
2021-05-26 |
アメリカ合衆国 |
がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
JP2022553389A
(ja)
|
2019-10-25 |
2022-12-22 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
|
|
US20210130438A1
(en)
*
|
2019-10-28 |
2021-05-06 |
The Broad Institute, Inc. |
Pan-cancer t cell exhaustion genes
|
|
CA3161104A1
(en)
|
2019-12-11 |
2021-06-17 |
Cecile Chartier-Courtaud |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
|
AU2020408017A1
(en)
|
2019-12-20 |
2022-07-14 |
Instil Bio (Uk) Limited |
Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
AU2021228701A1
(en)
*
|
2020-02-28 |
2022-09-15 |
KSQ Therapeutics, Inc. |
Methods for activation and expansion of tumor infiltrating lymphocytes
|
|
JP2020143057A
(ja)
*
|
2020-04-01 |
2020-09-10 |
アメリカ合衆国 |
がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
|
|
US12159700B2
(en)
|
2020-04-22 |
2024-12-03 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
US20230172987A1
(en)
|
2020-05-04 |
2023-06-08 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
TW202208616A
(zh)
*
|
2020-05-04 |
2022-03-01 |
美商艾歐凡斯生物治療公司 |
改良之腫瘤反應性ｔ細胞的選擇
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
TW202241468A
(zh)
|
2020-12-11 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者
|
|
EP4262827A1
(en)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
|
WO2022133140A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
WO2022130017A2
(en)
|
2020-12-18 |
2022-06-23 |
Instil Bio (Uk) Limited |
Processing of tumor infiltrating lymphocytes
|
|
JP2024500748A
(ja)
|
2020-12-18 |
2024-01-10 |
インスティル バイオ （ユーケイ） リミテッド |
腫瘍浸潤リンパ球の処理
|
|
WO2022130016A1
(en)
|
2020-12-18 |
2022-06-23 |
Instil Bio (Uk) Limited |
Tumor infiltrating lymphocytes and anti-cd47 therapeutics
|
|
US20240110152A1
(en)
|
2020-12-31 |
2024-04-04 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
|
EP4288140A1
(en)
|
2021-02-05 |
2023-12-13 |
Iovance Biotherapeutics, Inc. |
Adjuvant therapy for cancer
|
|
WO2022187741A2
(en)
|
2021-03-05 |
2022-09-09 |
Iovance Biotherapeutics, Inc. |
Tumor storage and cell culture compositions
|
|
EP4308691A1
(en)
|
2021-03-19 |
2024-01-24 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
|
IL306072A
(en)
|
2021-03-25 |
2023-11-01 |
Iovance Biotherapeutics Inc |
Methods and preparations for T-cell coculture potency assays and use with cellular therapy products
|
|
JP2024515189A
(ja)
|
2021-04-19 |
2024-04-05 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
|
|
EP4340850A1
(en)
|
2021-05-17 |
2024-03-27 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2023009716A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
EP4398915A1
(en)
|
2021-09-09 |
2024-07-17 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1 talen knockdown
|
|
CA3232700A1
(en)
|
2021-09-24 |
2023-03-30 |
Rafael CUBAS |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
CA3235824A1
(en)
|
2021-10-27 |
2023-05-04 |
Frederick G. Vogt |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
EP4430167A1
(en)
|
2021-11-10 |
2024-09-18 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
US20250101380A1
(en)
|
2022-01-28 |
2025-03-27 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
|
EP4565683A1
(en)
|
2022-08-01 |
2025-06-11 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
JP2025537155A
(ja)
|
2022-11-04 |
2025-11-14 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｃｄ３９／ｃｄ１０３選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張のための方法
|
|
JP2025539816A
(ja)
|
2022-11-21 |
2025-12-09 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
TW202509219A
(zh)
|
2023-07-13 |
2025-03-01 |
美商艾歐凡斯生物治療公司 |
編碼細胞介素之慢病毒載體及其用於製備腫瘤浸潤性淋巴球之用途
|
|
WO2025019790A1
(en)
|
2023-07-19 |
2025-01-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025171182A1
(en)
|
2024-02-08 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
|